Theorem Clinical Research

Plexxikon

Peter Hirth joins Trovagene's scientific advisory board

Friday, August 15, 2014 10:34 AM

Trovagene, a California-based developer of cell-free molecular diagnostics, has hired K. Peter Hirth, Ph.D., who joins the company's scientific advisory board. A pioneer in the field of personalized medicine, Hirth led the organizations that developed both Sutent and Zelboraf; two successful targeted cancer therapeutics.

More... »

Quest Diagnostics

Plexxikon selects Clinipace to manage trials

Friday, March 18, 2011 10:51 AM

Plexxikon, a company focused on the discovery and development of novel small molecule pharmaceuticals to treat human disease, has selected Clinipace Worldwide, a digital CRO, to manage all aspects of four clinical trials comprising a phase I healthy volunteer study, a phase Ib rheumatoid arthritis (RA) study and two phase II oncology studies. 
  
“We chose Clinipace Worldwide to manage these important clinical trials based on Clinipace’s commitment to customer service,” said Paul Lin, MD, MBA, director of business development at Plexxikon. “Plexxikon’s programs are highly differentiated from its competition, and we needed a highly differentiated CRO to get the job done.”

More... »


Plexxikon initiates phase II trial

Wednesday, March 9, 2011 10:50 AM

Plexxikon has treated its first patient in a phase II trial in Hodgkin lymphoma with PLX3397. This agent is an oral, selective inhibitor that down-modulates two key cell types thought to mediate the progression of Hodgkin lymphoma tumors: macrophages and mast cells.

More... »

Daiichi Sankyo acquires Plexxikon

Tuesday, March 1, 2011 12:35 PM

In another sign that biotechnology companies with promising pipelines are able to forge rich buyout deals, Japanese pharmaceutical company Daiichi Sankyo has announced it will pay $805 million upfront and up to $130 million in near-term milestones for Plexxikon, a tiny oncology developer, according to Fierce Biotech.

More... »


CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs